investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Role of Six1 and the miR106b 25 Cluster in EMT and Tumor Progression
Heide L Ford
1 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Adrian Harris
University of Oxford
Oxford, United Kingdom
Heide L Ford
University of Colorado Denver
Denver, United States
Related projects
William B Kinlaw
Fatty Acids and Cancer
Breast
Song Yao
Exome Array Analysis of Reproductive Aging and Breast Cancer in African Americans
Breast
Javed Khan
Targeting FGFR4, RAS, and PAX3-FOXO1 Gene in Rhabdomyosarcoma
Breast
Pediatric oncology or childhood cancer
Alvaro Monteiro
Charting the BRCT Domain Network
Breast
Ralph Scully
Analysis of BRCA1 Recombination Functions
Breast
Maria Jasin
HOMOLOGY-DIRECTED DNA REPAIR PROTEINS BRCA2 AND RAD51 IN TUMOR RELEVANT TISSUES
Breast
Gregg B Fields
Mechanism and Inhibition of Collagenolytic Activity
Breast
Kent Hunter
Genetic Modifiers of Initiation and Progression of Mammary Cancer
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast
